These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30312565)

  • 1. Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions?
    Park JC; Chan AW; Wirth LJ
    J Oncol Pract; 2018 Oct; 14(10):603-605. PubMed ID: 30312565
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.
    Sze H; Blanchard P; Ng WT; Pignon JP; Lee AW
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1107-22. PubMed ID: 26568551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of primary gross tumor volume and standardized uptake value of
    Jin YN; Yao JJ; Wang SY; Zhang WJ; Zhou GQ; Zhang F; Cheng ZB; Ma J; Mo HY; Sun Y
    Tumour Biol; 2017 Jul; 39(7):1010428317717843. PubMed ID: 28671052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes.
    Xu T; Zhu G; He X; Ying H; Hu C
    Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results.
    He X; Xu J; Guo W; Jiang X; Wang X; Zong D
    Future Oncol; 2013 Oct; 9(10):1459-67. PubMed ID: 24106897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma.
    Liang Z; Wang S; Lin Z; Feng S; Cheng Z; Yang Y; Kuang Y; Fidelis C; Ullah S; Li F
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):643-51. PubMed ID: 26831498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.
    Li Y; Li W; He Q; Xu Y; Ren X; Tang X; Wen X; Yang X; Sun Y; Zeng J; Yun J; Liu N; Ma J
    Oncotarget; 2015 May; 6(15):13309-19. PubMed ID: 25965822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials.
    Wang M; Tian H; Li G; Ge T; Liu Y; Cui J; Han F
    Oncotarget; 2016 Jul; 7(30):48375-48390. PubMed ID: 27356743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of locoregionally advanced nasopharyngeal carcinoma treated with intensity modulated irradiation and platinum-based chemotherapy.
    Xu JH; Guo WJ; Bian XH; Wu JF; Jiang XS; Guo YS; He X
    Cancer Radiother; 2013; 17(4):297-303. PubMed ID: 23849438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of nasopharyngeal cancer.
    Lee AW; Lin JC; Ng WT
    Semin Radiat Oncol; 2012 Jul; 22(3):233-44. PubMed ID: 22687948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Wen YF; Qi B; Liu H; Mo HY; Chen QY; Li J; Huang PY; Ye YF; Zhang Y; Deng MQ; Guo X; Hong MH; Cao KJ; Mai HQ
    Clin Cancer Res; 2011 Apr; 17(8):2451-8. PubMed ID: 21487064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.
    Yan M; Kumachev A; Siu LL; Chan KK
    Eur J Cancer; 2015 Aug; 51(12):1570-9. PubMed ID: 26044925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
    Wang Y; Ding W; Chen C; Niu Z; Pan M; Zhang H
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C191-5. PubMed ID: 26506874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yao JJ; He XJ; Lawrence WR; Zhang WJ; Kou J; Zhang F; Zhou GQ; Wang SY; Sun Y
    Cell Physiol Biochem; 2018; 48(1):285-292. PubMed ID: 30011397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The best multimodal treatment for locally advanced nasopharyngeal carcinoma : An update of the MAC-NPC data].
    Becker-Schiebe M; Christiansen H
    Strahlenther Onkol; 2017 Oct; 193(10):856-858. PubMed ID: 28812097
    [No Abstract]   [Full Text] [Related]  

  • 19. [Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis].
    Yang AK; Liu TR; Guo X; Qi GL; Chen FJ; Guo ZM; Zhang Q; Zeng ZY; Chen WC; Li QL
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Mar; 43(3):218-23. PubMed ID: 18630287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.